[1] Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit[J].mAbs. 2019,11(8): 1443-1451.
[2] Zhang L, Mai W Q, Jiang W Y,et al.Sintilimab: a promising anti-tumor PD-1 antibody[J].J Front Oncol,2020,10: 594558.
[3] National Cancer Institute.Common terminology criteria for adverse events (CTCAE) Version 5.0[S].U.S.Department of Health and Human Services, 2017.
[4] 原国家食品药品监督管理总局. 药品不良反应报告和监测工作手册[EB/OL].( 2013-12-15)[2019-12-07].
[5] 赵文静,尹周一,王裕新,等.2024美国癌症统计报告解读及中美癌症流行情况对比[J/OL].肿瘤防治研究.
[6] 隋月, 李雨, 刘广宣. 信迪利单抗用药评价和分析[J]. 中南药学,2023,21(4):1087-1092.
[7] 中华医学会妇科肿瘤学分会. 妇科肿瘤免疫检查点抑制剂临床应用指南(2023版)[J/CD]. 肿瘤综合治疗电子杂志,2023,9(2):67-98.
[8] Martins F, Sofiya L, Sykiotis G P, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance[J]. Nat Rev Clin Oncol, 2019, 16(9): 563-80.
[9] Chen C H, Yu H S, Yu S.Cutaneous adverse events associated with immune checkpoint inhibitors: a review article[J]. Curr Oncol, 2022, 29: 2871-2886.
[10] 中华医学会内分泌学分会免疫内分泌学组. 免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020)[J]. 中华内分泌代谢杂志,2021,37(1):1-16.
[11] Mahmood S S, Fradley M G, Cohen J V, et al.Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol,2018,71(16) : 1755-1764.
[12] Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors[J]. J Immunother Cancer,2020,8(1):e000261.
[13] 赵菲菲, 李满, 杨楠,等. 信迪利单抗致不良反应文献分析[J]. 中国药房, 2022, 33(16): 2012-2016.
[14] 张彦景,宋晓坤. 免疫检查点抑制剂致多系统免疫相关不良事件的诊疗思路[J]. 中国全科医学, 2023,26(23):2930-2935.
[15] 邓林,任超,孙涛,等. 索拉非尼联合信迪利单抗致中毒性表皮坏死松解症1例[J]. 药物流行病学,2024,33(2):224-229.
[16] 刘维峰,白笑梅,杨晓宇,等. 信迪利单抗致甲状腺功能减退和糖尿病酮症酸中毒1例[J]. 中南药学,2023,21(2):547-550.
[17] 唐亚娟,夏维虎,徐丽婷,等. 信迪利单抗致免疫相关肺炎的临床特征及案例分析[J]. 临床医学研究与实践,2023,8(1):18-23.